Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Pang, Yu ^a   Zhang, Zhijian ^b   Wang, Yufeng ^a   Wang, Shengfen ^a   Song, Yuanyuan ^a   Zhao, Bing ^a   Zhou, Yang ^a   Ou, Xichao ^a   Li, Qiang ^a   Xia, Hui ^a   Zheng, Yang ^a   Fang, Xiangqun ^b   Zhao, Yanlin ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Beijing genotype; China; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide

Indexed keywords

GENOMIC DNA; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BEIJING GENOTYPE; CHINA; CLADISTICS; DNA EXTRACTION; DRUG RESISTANT TUBERCULOSIS; FEMALE; GENOTYPING TECHNIQUE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POPULATION STRUCTURE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; DRUG EFFECTS; GENETICS; GENOTYPE; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PATHOGENICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CHINA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PYRAZINAMIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85010991332     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02170-16     Document Type: Article

References (39)

1. World Health Organization. 2015. Global tuberculosis report 2014. WHO/HTM/TB/2015.22. World Health Organization, Geneva, Switzerland.
2. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Song Y, Shang Y, Wang S, Zhao YL. 2012. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS One 7:e32976. https://doi.org/10.1371/journal.pone.0032976.
3. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, Chen M, Zhao Y, Jiang S, Du X, He G, Li J, Wang S, Chen W, Xu C, Huang F, Liu X, Wang Y. 2014. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet 383:2057-2064. https://doi.org/10.1016/S0140-6736(13)62639-2.
4. Li WM, Wang SM, Li CY, Liu YH, Shen GM, Zhang XX, Niu TG, Gao Q, van Soolingen D, Kremer K, Duanmu HJ. 2005. Molecular epidemiology of Mycobacterium tuberculosis in China: a nationwide random survey in 2000. Int J Tuberc Lung Dis 9:1314-1319.
5. Wang L, Liu J, Chin DP. 2007. Progress in tuberculosis control and the evolving public-health system in China. Lancet 369:691-696. https://doi.org/10.1016/S0140-6736(07)60316-X.
6. Hong Kong Chest Service/British Medical Research Council. 1981. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet i:171-174.
7. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. https://doi.org/10.1093/infdis/jit352.
8. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. 2015. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 59:38-45. https://doi.org/10.1128/AAC.03931-14.
9. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjo M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. 2016. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 16:1185-1192. https://doi.org/10.1016/S1473-3099(16)30190-6.
10. Zhang Y, Shi W, Zhang W, Mitchison D. 2014. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr 2:MGM2-0023-2013. https://doi.org/10.1128/microbiolspec.MGM2-0023-2013.
11. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. 2014. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 58:364-369. https://doi.org/10.1128/AAC.01228-13.
12. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N Engl J Med 366:2161-2170. https://doi.org/10.1056/NEJMoa1108789.
13. Parwati I, van Crevel R, van Soolingen D. 2010. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 10:103-111. https://doi.org/10.1016/S1473-3099(09)70330-5.
14. Mokrousov I, Ly HM, Otten T, Lan NN, Vyshnevskyi B, Hoffner S, Narvskaya O. 2005. Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: clues from human phylogeography. Genome Res 15:1357-1364. https://doi.org/10.1101/gr.3840605.
15. Liang QF, Pang Y, Chen QY, Lin SF, Lin J, Zhao Y, Wei SZ, Zheng JF, Zheng SH. 2013. Genetic profile of tuberculosis among the migrant population in Fujian Province, China. Int J Tuberc Lung Dis 17:655-661. https://doi.org/10.5588/ijtld.12.0615.
16. Yang C, Luo T, Sun G, Qiao K, DeRiemer K, Mei J, Gao Q. 2012. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin Infect Dis 55:1179-1187. https://doi.org/10.1093/cid/cis670.
17. Wang J, Liu Y, Zhang CL, Ji BY, Zhang LZ, Shao YZ, Jiang SL, Suzuki Y, Nakajima C, Fan CL, Ma YP, Tian GW, Hattori T, Ling H. 2011. Genotypes and characteristics of clustering and drug susceptibility of Mycobacterium tuberculosis isolates collected in Heilongjiang Province, China. J Clin Microbiol 49:1354-1362. https://doi.org/10.1128/JCM.02274-10.
18. Zhang Z, Lu J, Liu M, Wang Y, Qu G, Li H, Wang J, Pang Y, Liu C, Zhao Y. 2015. Genotyping and molecular characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Infect 70:335-345. https://doi.org/10.1016/j.jinf.2014.11.008.
19. van Crevel R, Ottenhoff TH, van der Meer JW. 2002. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 15:294-309. https://doi.org/10.1128/CMR.15.2.294-309.2002.
20. Rios-Barrera VA, Campos-Pena V, Aguilar-Leon D, Lascurain LR, Meraz-Rios MA, Moreno J, Figueroa-Granados V, Hernandez-Pando R. 2006. Macrophage and T lymphocyte apoptosis during experimental pulmonary tuberculosis: their relationship to mycobacterial virulence. Eur J Immunol 36:345-353. https://doi.org/10.1002/eji.200535202.
21. Dormans J, Burger M, Aguilar D, Hernandez-Pando R, Kremer K, Roholl P, Arend SM, van Soolingen D. 2004. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin Exp Immunol 137:460-468. https://doi.org/10.1111/j.1365-2249.2004.02551.x.
22. Rhines AS. 2013. The role of sex differences in the prevalence and transmission of tuberculosis. Tuberculosis (Edinb) 93:104-107. https://doi.org/10.1016/j.tube.2012.10.012.
23. Hudelson P. 1996. Gender differentials in tuberculosis: the role of socioeconomic and cultural factors. Tuber Lung Dis 77:391-400. https://doi.org/10.1016/S0962-8479(96)90110-0.
24. Mokrousov I, Jiao WW, Sun GZ, Liu JW, Valcheva V, Li M, Narvskaya O, Shen AD. 2006. Evolution of drug resistance in different sublineages of Mycobacterium tuberculosis Beijing genotype. Antimicrob Agents Chemother 50:2820-2823. https://doi.org/10.1128/AAC.00324-06.
25. Ribeiro SC, Gomes LL, Amaral EP, Andrade MR, Almeida FM, Rezende AL, Lanes VR, Carvalho EC, Suffys PN, Mokrousov I, Lasunskaia EB. 2014. Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage. J Clin Microbiol 52:2615-2624. https://doi.org/10.1128/JCM.00498-14.
26. Portevin D, Gagneux S, Comas I, Young D. 2011. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog 7:e1001307. https://doi.org/10.1371/journal.ppat.1001307.
27. Hanekom M, Gey van Pittius NC, McEvoy C, Victor TC, Van Helden PD, Warren RM. 2011. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis (Edinb) 91:510-523. https://doi.org/10.1016/j.tube.2011.07.005.
28. Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP. 2013. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis 57:1081-1093. https://doi.org/10.1093/cid/cit452.
29. Lumb R, Bastion I, Carter R, Jelfs P, Keehner T, Sievers A. 2011. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2008 and 2009. A report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell Q Rep 35:154-161.
30. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. 2007. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 11:571-576.
31. Zhao LL, Chen Y, Chen ZN, Liu HC, Hu PL, Sun Q, Zhao XQ, Jiang Y, Li GL, Tan YH, Wan KL. 2014. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. Antimicrob Agents Chemother 58:3475-3480. https://doi.org/10.1128/AAC.02426-14.
32. Xia Q, Zhao LL, Li F, Fan YM, Chen YY, Wu BB, Liu ZW, Pan AZ, Zhu M. 2015. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother 59:1690-1695. https://doi.org/10.1128/AAC.04541-14.
33. Alame-Emane AK, Xu P, Pierre-Audigier C, Cadet-Daniel V, Shen X, Sraouia M, Siawaya JF, Takiff H, Gao Q, Gicquel B. 2015. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Int J Tuberc Lung Dis 19:679-684. https://doi.org/10.5588/ijtld.14.0768.
34. Rodriguez JC, Ruiz M, Lopez M, Royo G. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 20:464-467. https://doi.org/10.1016/S0924-8579(02)00239-X.
35. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. 2013. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med 188:97-102. https://doi.org/10.1164/rccm.201212-2328OC.
36. Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL. 2015. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. Environ Sci Technol 49:6772-6782. https://doi.org/10.1021/acs.est.5b00729.
37. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, van Soolingen D. 2012. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 50:428-434. https://doi.org/10.1128/JCM.05435-11.
38. Pang Y, Zhou Y, Wang S, Lu J, Lu B, He G, Wang L, Zhao Y. 2011. A novel method based on high resolution melting (HRM) analysis for MIRU-VNTR genotyping of Mycobacterium tuberculosis. J Microbiol Methods 86:291-297. https://doi.org/10.1016/j.mimet.2011.05.016.
39. Lu B, Zhao P, Liu B, Dong H, Yu Q, Zhao X, Wan K. 2012. Genetic diversity of Mycobacterium tuberculosis isolates from Beijing, China assessed by spoligotyping, LSPs and VNTR profiles. BMC Infect Dis 12:372. https://doi.org/10.1186/1471-2334-12-372.